ARTICLE ABSTRACT
As a condition of publication of phase III clinical trials, medical journals should insist on the release of all raw data and a written independent clinical audit.
Editorials and commentaries in some high-profile journals herald an upcoming revolution in personalised oncology. However, any new treatment can only be considered an advance if it.
Link to access the full article: https://www.ncbi.nlm.nih.gov/pubmed/22106997
Please Sign in (or Register) to view further.